Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of KHK4951 eye drops versus aflibercept in neovascular age-related macular degeneration
jRCT2031230401Phase 2Active, not recruiting
- Sponsor
- Kyowa Kirin
- Start
- Nov 2023
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
01
Overview
Phase 2, randomised, double-blind trial of KHK4951 in exudative macular degeneration (2 arms), sponsored by Kyowa Kirin. Primary endpoint: Loss of ≥15 ETDRS letters in BCVA from baseline. Started Nov 2023; status: active, not recruiting.
02
Drugs
KHK4951
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on jRCT2031230401.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230401.